欢迎访问《现代生物医学进展》编辑部！

目的：探讨脑舒通胶囊对阿尔茨海默病患者外周血中IL-6 和TNF-α 水平的影响，并观察脑舒通的临床疗效。方法：按年龄和病程将临床条件基本相同的患者随机分为两组：对照组15 例；观察组（氯沙坦）22 例。ELISA 检测血清IL-6 和TNF-α 的含量。采用的量表为MMSE、ADL、Pfeffer 功能活动调查表( POD) ，Fuld 物体记忆测验(FOM) ,快速词汇测验(RVR)评定临床疗效，在入组时、治疗后第12 周后评出。结果：对照组患者治疗前外周血中IL-6 为（310±34）ng/ml, 治疗后外周血中IL-6 为（270±21） ng/ml，治疗前后比较无明显差异（P>0.05）。观察组患者治疗前外周血中IL-6 为（321±38）ng/ml，治疗后外周血中IL-6 为（185± 19）ng/ml,治疗前后比较有统计学意义（P<0.05）。对照组患者治疗前外周血中TNF-α 为（150±27）ng/ml，治疗后外周血中TNF-α 为（135±21）ng/ml，治疗前后比较无明显差异（P>0.05）。观察组患者治疗前外周血中TNF-α 为（154±25）ng/ml，治疗后外周血中 TNF-α 为（97±14）ng/ml,治疗前后比较有统计学意义（P<0.05）。观察组与对照组相比，前者外周血中TNF-α 的含量明显降低。使用常规药物的对照组患者治疗前后MMSE、ADL、POD、FOM 及RVR 均无明显变化，而使用脑舒通胶囊的观察组患者治疗前后其MMSE、ADL、POD、FOM 及RVR 变化明显。结论：脑舒通可抑AD 患者外周血中炎症因子的表达，且产生了较好的临床效果。

英文摘要:

Objective: To investigate the brain Shu capsule on the IL-6 and TNF-α levels in peripheral blood of patients with Alzheimer disease and to observe the clinical effect of spironolactone brain. Methods：The course of the disease by age and clinical conditions will be essentially the same patients were randomly divided into two groups: control group (15 cases); observation group (l22 cases). ELISA was used to detect serum IL-6 and TNF-α levels. Scale used for the MMSE, ADL, Pfeffer Functional Activities Questionnaire (POD), Fuld Object Memory Test (FOM), fast Vocabulary Test (RVR) Assessment of clinical efficacy in into the group. Results：The peripheral blood of patients before treatment, IL-6 was (310±34) ng / ml, after treatment, IL-6 in peripheral blood was (270 ±21) ng / ml, no significant difference before and after treatment (P>0.05). Observed in peripheral blood of patients before treatment, IL-6 was (321 ±38) ng / ml, after treatment, IL-6 in peripheral blood was (185±19) ng / ml, before and after treatment was statistically significant (P<0.05) Control group of patients before treatment was TNF-α in peripheral blood (150±27) ng / ml, after treatment, TNF-α in peripheral blood was (135±21) ng / ml, no significant difference before and after treatment (P>0.05). Observed in peripheral blood of patients before treatment, TNF-αwas (154±25) ng / ml, after treatment, TNF-α in peripheral blood was (97±14) ng / ml, before and after treatment was statistically significant (P<0.05) Observed compared with the control group, the former TNF-α in peripheral blood were significantly reduced. Use of conventional drug control patients before and after treatment MMSE, ADL, POD, FOM, and no significant change in RVR, and use the brain Shu Capsule observation of their patients before and after treatment MMSE, ADL, POD, FOM and RVR changed significantly. Conclusion：The AD brain Shutong peripheral blood of patients could inhibit the expression of inflammatory cytokines, and produced a better clinical effect.

查看全文查看/发表评论下载PDF阅读器

关闭